RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5.0（3則評分）
  • 醫學
RhAPPcast

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. 6 天前

    RhAPPcast: Navigating Leflunomide Use in Pregnant Patients with Sjögren’s Syndrome

    Join Danielle Gatti Palumbo, PharmD, a clinical pharmacist and RhAPP Board member, alongside Monica Richey, NP, a renowned rheumatology specialist and educator, as they discuss a challenging and unexpected clinical case live from the RhAPP National Conference in Nashville, Tennessee. This special RhAPPcast episode explores a real-world scenario of a patient who unexpectedly became pregnant while on leflunomide, highlighting the complexities of medication management in autoimmune diseases. Monica shares her initial reaction, the steps taken to initiate the cholestyramine washout protocol, and the multidisciplinary approach needed to ensure both maternal and fetal safety. Danielle provides critical insights into the pharmacology of leflunomide, including its long half-life, the importance of drug clearance before conception, and patient counseling strategies. They also discuss broader considerations for disease management in women of childbearing age, the role of conventional DMARDs in rheumatology, and lessons learned from this case. Recorded live at the RhAPP National Conference, this engaging discussion offers valuable takeaways for rheumatology providers navigating pregnancy risks with immunosuppressive therapies. For more expert insights, visit RhAPP.org and explore the RhAPP ACE App for the latest in rheumatology education.

    15 分鐘

  2. 2月28日

    FAQ: According to the New 2024 ACR Guidelines, How Do You Treat LN?

    Stacey Johnson, NP, a rheumatology specialist at Montana Arthritis Center, discusses key updates in the 2024 American College of Rheumatology (ACR) guidelines for lupus nephritis, with a strong emphasis on minimizing glucocorticoid exposure to prevent long-term complications. The updated guidelines focus on achieving a daily glucocorticoid dose of 5 mg or less within six months of initiating therapy. This approach aims to reduce steroid-related adverse effects such as osteoporosis, cardiovascular risks, and metabolic disturbances while maintaining disease control. To achieve this, clinicians must closely monitor disease activity and tailor tapering strategies to each patient’s individual needs. Frequent patient assessments and laboratory monitoring play a crucial role in ensuring stability throughout the tapering process. Identifying early signs of disease worsening is essential to making timely adjustments and preventing potential flares. By adopting a personalized approach, healthcare providers can optimize outcomes and improve the long-term management of lupus nephritis. For more expert insights on lupus nephritis treatment strategies, visit the RhAPP website or explore additional educational content on the RhAPP ACE App.

    1 分鐘

  3. 2月26日

    FAQ: How Do You Interpret cDAPSA/DAPSA and MDA?

    Join Katie Springer, PA-C, a rheumatology specialist at Northwestern Medicine in Lake Forest, Illinois, as she dives into critical tools for measuring disease activity in psoriatic arthritis (PsA) and how they shape treatment strategies for improved patient outcomes. Accurate assessment of PsA requires disease-specific tools beyond traditional rheumatoid arthritis (RA) measures. The Disease Activity in Psoriatic Arthritis (DAPSA) score evaluates joint inflammation using tender and swollen joint counts, CRP levels, and patient-reported assessments. The clinical DAPSA (cDAPSA), an alternative version, removes CRP from the calculation, offering another method to track disease progression. For a comprehensive view of PsA’s impact, the Minimal Disease Activity (MDA) index goes beyond joint symptoms, assessing enthesitis, skin involvement, pain, function, and patient-reported outcomes. Achieving MDA is a key goal in treat-to-target strategies, guiding adjustments in therapy to improve long-term patient health. Clinical trials and real-world evidence highlight guselkumab’s efficacy in PsA treatment. The DISCOVER-2 trial found that 25% of biologic-naïve PsA patients on guselkumab achieved MDA by week 24, increasing to 40% over two years. Additionally, real-world registry data from CorEvitas showed that 80% of patients remained on guselkumab at six months, with one in four achieving low disease activity—reinforcing the effectiveness seen in clinical trials. Understanding and utilizing these PsA-specific disease activity measures helps rheumatology providers make informed treatment decisions and ensure sustained improvements in patient care. For more expert insights into rheumatology advancements, visit RhAPP.org or explore the RhAPP ACE App.

    4 分鐘

  4. 2月25日

    FAQ: According to the New 2024 ACR Guidelines for Lupus Nephritis, What Are the Treatment Goals For Patients With LN?

    Waiting on description

    3 分鐘

  5. 2月19日

    FAQ: How Do You Explain The Timing of Ixekizumab's Clinical Efficacy to Patients?

    Claudia Rivera Salas, DNP, a nurse practitioner at Pine Hollow Partners in East Lansing, Michigan, shares firsthand insights into the rapid efficacy of Ixekizumab in treating psoriasis and psoriatic arthritis. One of the most common questions patients ask is how quickly they can expect relief, and the answer is simple—fast. From the first injection, many patients begin to see significant improvement in their symptoms, including reduced inflammation, joint pain, stiffness, enthesitis, and dactylitis. By the three-month follow-up, clinical data aligns with real-world experiences, showcasing meaningful symptom relief. Claudia recounts patient stories of life-changing transformations—individuals who once hid their skin under long sleeves and struggled with daily activities due to joint pain now confidently enjoy time with their families at the beach, free from discomfort and embarrassment. Ixekizumab’s rapid onset of action not only improves physical symptoms but also restores quality of life, allowing patients to regain mobility and confidence in ways they never thought possible. For more expert insights on psoriasis and psoriatic arthritis treatments, visit the RhAPP website, explore the Content Rheum hub, and access the latest educational materials on the RhAPP ACE App.

    2 分鐘

  6. 2月14日

    FAQ: 2024 ACR Guidelines: Screening & Diagnosing Lupus Nephritis in SLE Patients

    Monica Richey, NP, a seasoned rheumatology specialist with two decades of experience, provides an in-depth review of the 2024 lupus nephritis screening and diagnosis guidelines. As systemic lupus erythematosus (SLE) remains a leading cause of kidney-related complications, early detection and accurate diagnostic methods are essential for improving patient outcomes. This expert-led discussion explores the latest best practices for lupus nephritis screening, emphasizing why the spot protein-to-creatinine ratio has become the preferred diagnostic tool over the traditional 24-hour urine collection. The shift aims to provide a more efficient and practical approach to identifying early kidney involvement in SLE patients. Monica highlights the importance of performing full urinalysis at every patient visit, a practice that allows for earlier intervention and better disease management. The discussion also covers when healthcare providers should consider a kidney biopsy to confirm a lupus nephritis diagnosis and determine disease severity. Understanding lupus nephritis classifications and chronicity is crucial for tailoring treatment strategies and preventing long-term kidney damage. Monica shares her real-world insights on proactive patient care, offering guidance on how frequent monitoring can lead to more effective disease control. For rheumatology professionals, nephrologists, and caregivers, this video provides a comprehensive overview of the evolving landscape of lupus nephritis diagnosis. By staying informed on the latest screening recommendations, healthcare providers can enhance their approach to patient care and contribute to improved outcomes in lupus management. For more expert discussions on the latest advancements in rheumatology, visit RhAPP.org or explore the RhAPP ACE App.

    3 分鐘

  7. 2月11日

    RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines

    In this episode of RhAPPcast, Amanda Mixon, PA-C, President of RhAPP and a practicing physician assistant in Northern Colorado, is joined by Jennifer Mylod, NP, a seasoned rheumatology provider at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, to discuss the latest American College of Rheumatology (ACR) guideline updates for lupus nephritis. With the first ACR guideline update since 2012, these new recommendations reflect advancements in therapeutics and a shift toward more targeted treatment approaches. The episode explores key changes, including updated recommendations for lower-dose glucocorticoids, the introduction of triple therapy strategies, and the importance of early intervention in preventing irreversible kidney damage. The discussion also highlights screening protocols, emphasizing the need for regular urine protein monitoring in lupus patients every six to twelve months to detect early signs of kidney involvement. One of the most significant shifts in the guidelines is the preference for triple therapy over dual therapy for patients with active lupus nephritis. This new approach integrates glucocorticoids with mycophenolate mofetil (MMF) or cyclophosphamide, combined with an additional immunosuppressive agent such as belimumab or a calcineurin inhibitor. The rationale behind this shift is to reduce long-term steroid exposure while improving renal outcomes. The conversation dives into the evidence supporting these recommendations and how providers can implement them effectively in clinical practice. Beyond treatment selection, the discussion touches on the importance of shared decision-making and addressing healthcare disparities in lupus care. Patients from diverse socioeconomic backgrounds often face barriers to timely treatment, which can significantly impact their prognosis. By fostering strong patient-provider relationships and ensuring open communication, rheumatology teams can better support patients in managing their disease and adhering to treatment plans. With advancements in lupus nephritis management, providers now have more tools than ever to improve patient outcomes. The insights shared in this episode aim to equip healthcare professionals with the knowledge and strategies needed to implement the latest guidelines in their practice. Stay informed on evolving lupus nephritis research, treatment guidelines, and clinical insights by visiting RhAPP.org or accessing the latest educational content on the RhAPP ACE App.

    27 分鐘

  8. 2月7日

    FAQ: How is Lupus Nephritis Defined?

    Join Amanda Mixon, PA-C, President of RhAPP and a practicing physician assistant in Northern Colorado, as she highlights the critical role of early detection and management in lupus nephritis. With up to 50% of lupus patients developing kidney involvement, proactive screening and timely intervention are essential to preventing severe complications, including end-stage renal disease (ESRD). Lupus nephritis results from autoantibody-driven kidney inflammation, leading to proteinuria, hypertension, and progressive kidney damage. Without proper management, up to 30% of patients face a 10-year mortality rate, while 10-20% may progress to ESRD. The latest American College of Rheumatology (ACR) guidelines emphasize routine urine protein screening every six to twelve months for lupus patients, with more frequent monitoring in those with known kidney disease. Patients who fail to achieve complete renal response should have kidney function and protein levels checked at least every three months, with biopsy considered for persistent proteinuria or unexplained kidney function decline. By following updated screening recommendations and initiating treatment early, clinicians can help preserve kidney function and improve long-term outcomes. Stay informed on the latest lupus nephritis research, treatment strategies, and expert discussions by visiting RhAPP.org or accessing educational content on the RhAPP ACE App.

    2 分鐘
顯示全部 (72)

評分與評論

5
（滿分 5 顆星）
3 則評分

簡介

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

資訊

  • 創作者
    Rheumatology Advanced Practice Providers (RhAPP)
  • 活躍年代
    2023年 - 2025年
  • 集數
    72
  • 年齡分級
    兒少適宜
  • 版權
    © 2025 RhAPPcast
  • 節目網站
    RhAPPcast

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大